A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of GR1802 Injection in Combination With Background Therapy in Patients With SAR

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Voluntarily sign the informed consent form.

• Seasonal allergic rhinitis has been prevalent for at least 2 years.

• Poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past.

• Positive serum-specific IgE test results.

• Symptom severity scores for the season met the enrollment criteria.

Locations
Other Locations
China
Zhongnan Hospital of Wuhan university
RECRUITING
Wuhan
Contact Information
Primary
liaison officer
fangxiaoyan@genrixbio.com
021-50805988-8039
Time Frame
Start Date: 2025-08-15
Estimated Completion Date: 2026-07-31
Participants
Target number of participants: 150
Treatments
Experimental: Interleukin-4 receptor responder
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Genrix (Shanghai) Biopharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials